Recent Updates
Recently added Catalysts
JNJ Positive Sentiment Score: 85/100

media-relations its.jnj.com Investor contact investor-relations its.jnj.com FOR IMMEDIATE RELEASE Johnson Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors New Brunswick, New J

Key Takeaway: Johnson & Johnson has elected Daniel Pinto, President of JPMorganChase, to its Board of Directors. Pinto's extensive experience in financial leadership and global capital markets is expected to add significant value to the board. He expressed admiration for J&J's commitment to healthcare innovation and improving patient outcomes. This strategic appointment may enhance J&J's initiatives in advancing healthcare solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Daniel Pinto brings deep financial expertise to the board.
  • His experience in global capital markets is a tremendous asset.
  • Pinto admires J&J's investment in scientific innovation.
  • The addition of Pinto signals confidence in J&J's future.

Full Press Release Details

Exhibit 99.1
Media contact media-relations its.jnj.com Investor contact investor-relations its.jnj.com
Johnson Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
New Brunswick, New Jersey (June 10, 2025) - Johnson Johnson (NYSE JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors.
"We are thrilled to have Daniel join Johnson Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson Johnson as we continue to invest in and advance the next generation of healthcare innovation for patients."
"I've long admired Johnson Johnson's continued investment in scientific innovation and its commitment to improving health outcomes for patients facing the most challenging diseases," said Daniel Pinto. "It's an honor to join Johnson Johnson's board of directors and serve alongside board members who are dedicated to improving the health and well-being of communities around the world."
Mr. Pinto is a prominent business leader with more than three decades of financial expertise helming critical leadership roles within JPMorganChase, one of the world's preeminent global financial services firms, where he currently serves as President and as a member of the Company's Operating Committee.
Mr. Pinto has spent his career at JPMorganChase and its predecessor companies. He began as a financial analyst and foreign exchange trader at Manufacturers Hanover in 1983 in Buenos Aires. In 1992, he was appointed head of Sales for Chemical Bank and, shortly after, became head trader and Treasurer of Chemical Bank in Mexico. Daniel moved to London in 1996 to oversee local markets in Eastern Europe, the Middle East, Africa and Asia for Chase Manhattan, later taking charge of the markets side of the firm's emerging-market business.
In early 2006, Mr. Pinto was made global head of Emerging Markets, later expanding his remit to include Global Credit Trading Syndicate and Global Fixed Income for the Investment Bank. He was made co-CEO of the Corporate Investment Bank in 2012 and became sole CEO in 2014.
In January 2018, he was named Co-President and Chief Operating Officer of JPMorganChase to work closely with the CEO and the Board to identify and pursue critical firmwide opportunities. He became sole President and COO in January 2022. In January 2025, he announced that he would retire from the company at the end of 2026. He retains the role of President until June 30th, 2025, and will then serve as Vice Chairman of the company through 2026.
Mr. Pinto holds a bachelor's degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires. He is a member of the Board of Directors of the Institute of International Finance.
About Johnson Johnson
At Johnson Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https www.jnj.com .

Frequently Asked Questions

Who was recently elected to Johnson & Johnson's Board of Directors?

Daniel Pinto, President of JPMorganChase, has been elected to the Board.

What does Daniel Pinto bring to Johnson & Johnson's Board?

He brings deep financial expertise and a global capital markets perspective.

What is Daniel Pinto's background in finance?

He has over 30 years of experience at JPMorganChase in various leadership roles.

When will Daniel Pinto retire from JPMorganChase?

He will retire at the end of 2026, remaining as President until June 2025.

What is Johnson & Johnson's mission in healthcare?

They aim to innovate in healthcare to improve health outcomes for patients.

Last updated: Jun 10, 2025